Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Kevin J. Harrington, Robert L. Ferris, Maura Gillison, Makoto Tahara, Athanasios Argiris, Jérôme Fayette, Michael Schenker, Åse Bratland, John W. T. Walker, Peter Grell, Caroline Even, Christine H. Chung, Rebecca Redman, Alexandre Coutte, Sébastien Salas, Cliona Grant, Sergio de Azevedo, Denis Soulières, Aaron R. Hansen, Li Wei, Tariq Aziz Khan, Karen Miller-Moslin, Mustimbo Roberts, Robert Haddad

Open source

DOI: 10.1001/jamaoncol.2023.0147
Published: 2023-06-01
Container: JAMA Oncology
Publisher: American Medical Association (AMA)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamaoncol.2023.0147,
  title = {Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck},
  author = {Kevin J. Harrington and Robert L. Ferris and Maura Gillison and Makoto Tahara and Athanasios Argiris and Jérôme Fayette and Michael Schenker and Åse Bratland and John W. T. Walker and Peter Grell and Caroline Even and Christine H. Chung and Rebecca Redman and Alexandre Coutte and Sébastien Salas and Cliona Grant and Sergio de Azevedo and Denis Soulières and Aaron R. Hansen and Li Wei and Tariq Aziz Khan and Karen Miller-Moslin and Mustimbo Roberts and Robert Haddad},
  year = {2023},
  journal = {JAMA Oncology},
  doi = {10.1001/jamaoncol.2023.0147},
  url = {https://doi.org/10.1001/jamaoncol.2023.0147}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
AU  - Kevin J. Harrington
AU  - Robert L. Ferris
AU  - Maura Gillison
AU  - Makoto Tahara
AU  - Athanasios Argiris
AU  - Jérôme Fayette
AU  - Michael Schenker
AU  - Åse Bratland
AU  - John W. T. Walker
AU  - Peter Grell
AU  - Caroline Even
AU  - Christine H. Chung
AU  - Rebecca Redman
AU  - Alexandre Coutte
AU  - Sébastien Salas
AU  - Cliona Grant
AU  - Sergio de Azevedo
AU  - Denis Soulières
AU  - Aaron R. Hansen
AU  - Li Wei
AU  - Tariq Aziz Khan
AU  - Karen Miller-Moslin
AU  - Mustimbo Roberts
AU  - Robert Haddad
PY  - 2023
JO  - JAMA Oncology
DO  - 10.1001/jamaoncol.2023.0147
UR  - https://doi.org/10.1001/jamaoncol.2023.0147
ER  -

APA

Harrington, K. J., Ferris, R. L., Gillison, M., Tahara, M., Argiris, A., Fayette, J., Schenker, M., Bratland, Å., Walker, J. W. T., Grell, P., Even, C., Chung, C. H., Redman, R., Coutte, A., Salas, S., Grant, C., Azevedo, S. D., Soulières, D., Hansen, A. R., Wei, L., Khan, T. A., Miller-Moslin, K., Roberts, M., & Haddad, R. (2023). Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2023.0147

Source records

crossref · retrieved 2026-09-27T02:30:02.030Z